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Abstract
Background: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and 
determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, 
we evaluated the prevalence and risk factors of significant hepatic fibrosis in this group using the aspartate 
aminotransferase (AST)-to-platelet ratio index (APRI).
Methods: We conducted a cross-sectional study among HIV-infected patients negative for hepatitis B surface antigen 
and hepatitis C antibody in the Penn Center for AIDS Research Adult/Adolescent Database. Clinical and laboratory data 
were collected from the database at enrollment. Hypothesized determinants of significant fibrosis were modifiable risk 
factors associated with liver disease progression, hepatic fibrosis, or hepatotoxicity, including immune dysfunction (i.e., 
CD4 T lymphocyte count <200 cells/mm3, HIV viremia), diseases associated with hepatic steatosis (e.g., obesity, 
diabetes mellitus), and use of antiretroviral therapy. The primary outcome was an APRI score >1.5, which suggests 
significant hepatic fibrosis. Multivariable logistic regression identified independent risk factors for significant fibrosis by 
APRI.
Results: Among 432 HIV-monoinfected patients enrolled in the CFAR Database between November 1999 and May 
2008, significant fibrosis by APRI was identified in 36 (8.3%; 95% CI, 5.9 - 11.4%) patients. After controlling for all other 
hypothesized risk factors as well as active alcohol use and site, detectable HIV viremia (adjusted OR, 2.56; 95% CI, 1.02 - 
8.87) and diabetes mellitus (adjusted OR, 3.15; 95% CI, 1.12 - 10.10) remained associated with significant fibrosis by APRI.
Conclusions: Significant fibrosis by APRI score was found in 8% of HIV-monoinfected patients. Detectable HIV viremia 
and diabetes mellitus were associated with significant fibrosis. Future studies should explore mechanisms for fibrosis in 
HIV-monoinfected patients.
Background
As survival of HIV-infected individuals has improved
with widespread use of combination antiretroviral ther-
apy (ART), non-HIV-related conditions are now common
causes of morbidity among HIV-infected patients in the
developed world. In particular, liver disease has emerged
as an increasingly significant contributor to mortality
among HIV-infected patients due to the high prevalence
of viral hepatitis coinfection [1]. However, additional fac-
tors apart from viral hepatitis could contribute to hepatic
fibrosis, including antiretroviral medications [2,3], con-
comitant metabolic diseases [4], and immunosuppression
[5]. Consequently, HIV-infected patients without viral
hepatitis coinfection might also be at risk for liver disease.
However, few studies have examined the prevalence and
potential risk factors for significant hepatic fibrosis
among HIV-monoinfected patients (i.e., those without
viral hepatitis coinfection) [2,6,7]. Identifying risk factors,
particularly those that are modifiable, could help reduce
the risk of liver disease in this population, especially as it
ages.
To address this issue, we evaluated the prevalence and
risk factors for significant hepatic fibrosis among HIV-
monoinfected patients. Since liver biopsy results are gen-
erally not available on sufficiently large numbers of HIV-
monoinfected patients to permit appropriate epidemio-
logic analyses, we used a non-invasive measure of signifi-
cant liver fibrosis, the aspartate aminotransferase (AST)-
to-platelet ratio index (APRI). This index has previously
been validated as a surrogate marker of significant
* Correspondence: vincentl@mail.med.upenn.edu
2 Division of Infectious Diseases, Department of Medicine, University of 
Pennsylvania School of Medicine, Philadelphia, PA, USA
Full list of author information is available at the end of the article
DallaPiazza et al. BMC Infectious Diseases 2010, 10:116
http://www.biomedcentral.com/1471-2334/10/116
Page 2 of 7
hepatic fibrosis in HIV/HCV-coinfected patients [8-10],
and has recently been used to determine advanced fibro-
sis in HIV-monoinfected patients [2]. Our hypothesized
determinants of significant fibrosis were modifiable risk
factors associated with liver disease progression, hepatic
fibrosis, or hepatotoxicity, including immune dysfunction
(i.e., CD4 T lymphocyte count <200 cells/mm3, HIV vire-
mia) [11], diseases associated with hepatic steatosis (e.g.,
obesity, diabetes mellitus) [12-14], and ART use [15,16].
Methods
Study Design and Patients
We conducted a cross-sectional study of patients enrolled
in the Penn Center for AIDS Research (CFAR) Adult/
Adolescent Database. This patient registry was initiated
in November 1999 to track demographic, clinical, and
laboratory data from HIV-infected patients cared for at
four University of Pennsylvania-affiliated adult-care hos-
pitals (i.e., Hospital of the University of Pennsylvania
[HUP], Penn Presbyterian Medical Center [PPMC], Phil-
adelphia Veterans Affairs Medical Center, and Pennsylva-
nia Hospital) and at the adolescent HIV clinic at the
Children's Hospital of Philadelphia [17]. Subjects enrolled
from the HUP, PPMC, and Pennsylvania Hospital sites
are comparable with regards to age, sex, race, and ethnic-
ity, but given different eligibility rules, the adolescent HIV
clinic at the Children's Hospital of Philadelphia provides
care to younger patients while the Philadelphia Veterans
Affairs Medical Center cares for a primarily male popula-
tion. Subjects in the Penn CFAR Database have labora-
tory-confirmed HIV infection, provide informed consent,
and complete a standardized questionnaire that collects
demographic, medical, psychosocial, and HIV data.
Additional laboratory data, such as results of hepatitis B
surface antigen (HBsAg; Elecsys 2010; Roche Diagnostics,
Indianapolis, IN), hepatitis C virus (HCV) antibody (anti-
HCV; Abbott HCV EIA 2.0 or 3.0 enzyme immunoassay;
Abbott Laboratories, Abbott Park, IL), liver aminotrans-
ferases, and platelet counts, can be downloaded into the
Penn CFAR Database from hospital laboratory computer
systems at the HUP and PPMC sites. The study was
approved by the Institutional Review Board of the Uni-
versity of Pennsylvania.
All HBsAg-negative/anti-HCV-negative patients
enrolled in the CFAR database at the HUP and PPMC
sites between November 1, 1999 and May 31, 2008 were
eligible for inclusion. A total of 400 patients was targeted
to have 80% power to detect a 20% difference in the prev-
alence of significant liver fibrosis by APRI score between
those with and without each risk factor of interest.
Study Outcome
The main study outcome was significant fibrosis as deter-
mined by APRI score, a non-invasive measure of signifi-
cant liver fibrosis. The APRI score is defined as: (AST[/
ULN]*100/platelet count[109/L]) [18]. APRI accurately
represents liver fibrosis only when liver disease has
reached a significantly severe stage. An APRI score >1.5
has been shown to be predictive of significant liver fibro-
sis (defined as an Ishak fibrosis score >3) with an area
under the receiver operating characteristic curve of 0.76-
0.85 [9,10,18]. Thus, we used the established cutoff of 1.5
to determine the presence of significant fibrosis.
Data Collection
All data were collected from the Penn CFAR Database at
subjects' enrollment and included: date of birth; sex; race/
ethnicity; duration of HIV diagnosis; risk factors for HIV;
self-reported alcohol use within the past 30 days (yes/no);
self-reported marijuana use in the last 30 days (yes/no);
diabetes mellitus (based on a random glucose level
greater than 200 mg/dL and/or self-reported use of an
anti-diabetic medication); obesity (defined as body mass
index (BMI) ≥ 30 kg/m2); use of ART (defined as receipt
of three antiretroviral medications from at least two dif-
ferent drug classes) [19]; CD4 cell count; HIV viral load
(determined by Versant HIV-1 RNA 3.0 Assay; Bayer
Diagnostics; lower limit of detection: 75 copies/mL);
AST; and platelet count.
Statistical analysis
BMI was calculated as body weight (kg)/height2 (m2). Dif-
ferences between patients with and without significant
fibrosis by APRI score were assessed using Chi-square or
Fisher's exact tests, as indicated, for categorical data and
Wilcoxon rank-sum tests for continuous data.
Multivariable logistic regression was used to determine
risk factors for significant fibrosis by APRI score.
Hypothesized risk factors for significant fibrosis included
a CD4 cell count below 200 cells/mm3, detectable HIV
viremia (HIV viral load >75 copies/mL), diabetes melli-
tus, obesity, and ART use. Potential confounders evalu-
ated included age; sex; race/ethnicity; CFAR site;
duration of HIV; HIV risk factors; alcohol use; and mari-
juana use. Further model reduction was achieved by elim-
inating factors that proved to be potential risk factors
only infrequently in 1000 bootstrap samples of the data
[20]. Robust 95% confidence intervals (CIs) that do not
depend on large-sample assumptions were then esti-
mated using bias-corrected (accelerated) bounds from
another round of 999 bootstrap re-samples [20]. All data
were analyzed using Stata 10.1 (Stata Corp, College Sta-
tion, TX).
Results
Among 1,533 HIV-infected patients enrolled in the CFAR
Database through May 31, 2008, 590 (38%) were from the
HUP and PPMC sites. Among these patients, 50 (8%)
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were HBsAg-positive, 106 (18%) were anti-HCV-positive,
2 (0.3%) were HBsAg-positive and anti-HCV-positive,
and 432 (73%) were HIV-monoinfected. The baseline
characteristics of the 432 HIV-monoinfected subjects are
shown in Table 1. Consistent with the population served
by the affiliated hospitals, subjects in this study were pri-
marily male (59%) and African American (72%). The
majority (63%) received ART, and the median duration of
HIV diagnosis was 2 years (interquartile range [IQR], 1 -
7 years). The median CD4 cell count was 340 cells/mm3
(IQR, 177 - 516 cells/mm3), and the median HIV viral
load was 4,950 copies/mL (IQR, 75 - 44,162 copies/mL).
Thirty-six patients (8.3%; 95% CI, 5.9 - 11.4%) had sig-
nificant liver fibrosis as determined by APRI score. Age;
sex; race; ethnicity; BMI; duration of HIV diagnosis; use
of ART, alcohol, and marijuana; and median CD4 cell
count were similar between subjects with and without
significant fibrosis by APRI score (Table 1). Patients with
significant fibrosis were more likely to have diabetes mel-
litus (6 [17%] versus 28 [7%]; p = 0.04) and detectable HIV
viremia (32 [89%] versus 291 [73%]; p = 0.0004).
Table 2 shows results of the multivariable analysis with
bootstrap re-sampling examining risk factors for signifi-
cant fibrosis by APRI. After controlling for all other
hypothesized risk factors as well as active alcohol use and
site, detectable HIV viremia (adjusted OR, 2.56; 95% CI,
1.02 - 8.87) and diabetes mellitus (adjusted OR, 3.15; 95%
CI, 1.12 - 10.10) remained associated with significant
fibrosis by APRI score. CD4 count below 200 cells/mm3,
obesity, and ART use did not increase the risk of signifi-
cant fibrosis. Additionally, when we examined CD4 cell
count as a continuous variable, the OR of significant
fibrosis did not decrease with each 50 cells/mm3 increase
in CD4 cell count (adjusted OR, 0.98; 95% CI, 0.90 - 1.06).
Discussion
In this study, we found the prevalence of significant liver
fibrosis as determined by APRI score to be 8.3% among
HIV-monoinfected patients. In addition, both diabetes
mellitus and HIV viremia were risk factors for significant
fibrosis by APRI in this sample. Other hypothesized risk
factors, including CD4 count below 200 cells/mm3, obe-
sity, and ART use were not associated with significant
fibrosis by APRI score.
The prevalence of significant liver fibrosis among HIV-
monoinfected patients in this study sample is consistent
with a prior cross-sectional study conducted among
1,845 HIV-infected patients without viral hepatitis at the
Johns Hopkins HIV Clinic, which showed that 7% of
these patients had significant hepatic fibrosis as deter-
mined by APRI >1.5 [7]. Predictors of significant fibrosis
included CD4 cell count ≥ 200 cells/mm3 (adjusted OR,
0.29; 95% CI, 0.12 - 0.69), random glucose ≥ 140 mg/dL
(adjusted OR, 2.76; 95% CI, 1.06 - 7.16), and active ART
use (adjusted OR, 2.93; 95% CI, 1.22 - 7.03). In contrast, a
cross-sectional analysis among 1,307 HIV-monoinfected
patients receiving care at an HIV clinic in Spain showed
that only 1% had significant liver fibrosis as measured by
transient elastometry [6]. Differences in the non-invasive
methods to measure hepatic fibrosis and in the study
populations might account for the disparate results.
Our study found that diabetes mellitus was a risk factor
for significant liver fibrosis among HIV-monoinfected
patients. The biological mechanism underlying the asso-
ciation between diabetes and liver fibrosis remains poorly
understood. Diabetes can promote hepatic steatosis [21],
which can lead to hepatic fibrosis, but additional evi-
dence suggests that diabetes can induce liver fibrosis
independent of steatosis and visceral obesity [14]. This
mechanism may be related to the ability of insulin to
stimulate hepatic stellate cells [22]. Among HIV-unin-
fected patients, diabetes mellitus has been associated
with advanced liver fibrosis in patients with chronic HCV
infection [23-25]. Further, several studies have identified
diabetes as determinant of advanced fibrosis [26,27] and
increased fibrosis progression [28] among HIV-unin-
fected patients with nonalcoholic fatty liver disease. We
were unable to explore the impact of severity of diabetes
(e.g., hemoglobin A1c) and anti-diabetic medications on
significant fibrosis since the Penn CFAR Adult/Adoles-
cent Database does not collect data on these variables.
Additional research is needed to examine how diabetes
and its treatment might contribute to hepatic fibrosis in
HIV and to evaluate the effect of glycemic control on liver
fibrosis progression in HIV.
Another risk factor for significant hepatic fibrosis
among HIV-monoinfected patients in this sample was
HIV viremia. The influence of HIV viremia on hepatic
fibrosis in HIV-monoinfected individuals is unclear.
However, among HIV/HCV-coinfected patients, HIV
accelerates the progression of hepatic fibrosis. In addi-
tion, a shorter time with an undetectable HIV viral load
has been shown to increase the risk of hepatic decompen-
sation among HIV/HCV-coinfected patients [11]. Results
from the Strategies for Management of Antiretroviral
Therapy (SMART) study showed that rates of hepatic dis-
ease were significantly higher among HIV-infected
patients who interrupted ART compared with those who
maintained it [29]. Our results are consistent with find-
ings from in vitro studies in which HIV has been shown
to enter and replicate in hepatic stellate cells and directly
promote hepatic fibrosis [30]. Future studies should fur-
ther evaluate this and other potential mechanisms by
which HIV increases the risk of liver fibrosis.
Importantly, ART use was not associated with signifi-
cant fibrosis. In this cross-sectional study, we were not
able to assess the duration of exposure to ART. However,
our finding is consistent with a recent report demonstrat-
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Table 1: Baseline subject characteristics, overall and by significant fibrosis as determined by AST-to-platelet ratio index 
(APRI) score (APRI >1.5).
Characteristic All Subjects (n = 432) APRI ≤ 1.5 (n = 396) APRI >1.5 (n = 36) P-Value
Median age (yrs, IQR) 38 (32-44) 38 (31-44) 39 (35-45) 0.4
Male sex (no., %) 254 (59%) 228 (58%) 26 (72%) 0.09
Race (no., %)
African-American 311 (72%) 286 (72%) 25 (69%) 0.7
Caucasian 121 (28%) 110 (28%) 11 (31%)
Hispanic (no., %) 17 (4%) 16 (4%) 1 (3%) 0.7*
Alcohol use in last 30 days (no., %) 185 (43%) 167 (42%) 18 (50%) 0.4
Marijuana use in last 30 days (no., %) 81 (19%) 72 (18%) 9 (25%) 0.3
Diabetes mellitus (no., %) 34 (8%) 28 (7%) 6 (17%) 0.04
Body mass index (kg/m2, IQR) 0.1*
Underweight (≤ 18.4 kg/m2) 15 (3%) 14 (4%) 1 (3%)
Ideal (18.5 kg/m2 - 24.9 kg/m2) 202 (47%) 179 (45%) 23 (64%)
Overweight (25.0 kg/m2 - 29.9 kg/m2) 135 (31%) 128 (32%) 7 (19%)
Obese (30 kg/m2 - 39.9 kg/m2) 65 (15%) 60 (15%) 5 (14%)
Very Obese (≥ 40.0 kg/m2) 15 (3%) 15 (4%) 0
Median duration of HIV (yrs, IQR) 2 (1-7) 2 (0-7) 2 (0-9.5) 0.8
On antiretroviral therapy (no., %) 273 (63%) 252 (63%) 21 (58%) 0.5
Lopinavir/ritonavir (no., %)
Prior 175 (41%) 159 (40%) 16 (44%) 0.6
Current 74 (17%) 68 (17%) 6 (17%) 0.9
Nevirapine (no., %)
Prior 67 (16%) 61 (15%) 6 (17%) 0.8
Current 12 (3%) 12 (3%) 0 (0%) 0.3*
Didanosine (no., %)
Prior 57 (13%) 55 (14%) 2 (6%) 0.2*
Current 11 (3%) 11 (3%) 0 (0%) 0.3*
Stavudine (no., %)
Prior 84 (19%) 78 (20%) 6 (17%) 0.7
Current 11 (3%) 5 (2%) 0 (0%) 0.5*
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Zidovudine/lamivudine/abacavir (no., %)
Prior 35 (8%) 33 (8%) 2 (6%) 0.6
Current 8 (2%) 8 (2%) 0 (0%) 0.4
Median CD4 count (cells/mm3, IQR) 340 (177-516) 342 (182-516) 315 (58-534) 0.3
CD4 count <200 cells/mm3 (no., %) 121 (28%) 107 (27%) 14 (39%) 0.1
Median HIV viral load (copies/mL, IQR) 4,950 (75-44,162) 2,506 (75-33,228) 38,517 (2,958-
206,373)
0.0004
HIV viral load category (no., %)
75-49,999 copies/mL 331 (76%) 311 (78%) 20 (56%) 0.003*
50,000-99,999 copies/mL 33 (8%) 30 (8%) 3 (8%)
≥ 100,000 copies/mL 68 (16%) 55 (14%) 13 (36%)
Detectable HIV viremia (>75 copies/mL) 323 (75%) 291 (73%) 32 (89%) 0.04
Median aspartate aminotransferase (U/L, IQR) 39 (23-42) 29 (23-37) 84 (65-123) <0.001
Median platelet count (×109/L, IQR) 232 (187-283) 237 (197-287) 130 (92-163) <0.001
Median APRI 0.42 (0.31-0.66) 0.40 (0.30-0.59) 2.1 (1.7-80-3.64) <0.001
* P-values for differences between subjects determined by Fisher's exact test
IQR = interquartile range
Table 1: Baseline subject characteristics, overall and by significant fibrosis as determined by AST-to-platelet ratio index 
(APRI) score (APRI >1.5). (Continued)
ing that ART has a negligible effect on liver fibrosis pro-
gression as measured by APRI in HIV-monoinfected
patients but is associated with an increase in fibrosis pro-
gression in HIV/HCV-coinfected individuals [2]. These
results suggest that while antiretrovirals may cause hepa-
totoxicity, their impact on fibrosis in HIV-monoinfected
patients may be limited. It is possible that older antiretro-
viral medications might have increased the risk of
advanced liver fibrosis, but that this effect could be coun-
terbalanced by a beneficial impact of newer regimens. We
did compare use of selected older non-nucleoside (i.e.,
nevirapine) and nucleoside (i.e., didanosine, stavudine,
and zidovudine) reverse transcriptase inhibitors between
patients with and without significant hepatic fibrosis and
found no differences in their use between the groups
(Table 1). Further research is needed into the long-term
effects of ART, and specific antiretroviral drugs, on the
liver in HIV monoinfection.
Our study had several limitations. First, since cross-
sectional studies evaluate exposure and disease status at
the same time, this study design is limited in its ability to
determine whether exposure preceded or resulted from
disease. However, since significant hepatic fibrosis is not
known to lead to the hypothesized risk factors of interest,
the cross-sectional design remains appropriate. This
design did limit our ability to evaluate change in variables
of interest over time.
Second, we identified only 36 subjects with significant
fibrosis, and this small number limits our statistical
power for identifying risk factors for this outcome. How-
ever, we used two stages of bootstrap re-sampling to eval-
uate predictors of interest and obtain robust estimates of
the association between these factors and significant
fibrosis.
Third, multivariable analyses may not entirely eliminate
residual confounding from unmeasured factors. In par-
ticular, duration of comorbid illnesses and cumulative
exposure to hepatotoxic medications might be associated
with hepatic fibrosis. The CFAR Database does not col-
lect frequency or quantity of alcohol use, duration of
comorbidities (e.g., diabetes mellitus), duration of ART
use, or use of non-antiretroviral medications that might
be hepatotoxic (e.g., acetaminophen, metformin). We
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therefore could not examine the relationship between
these variables and significant fibrosis.
Fourth, patients in our sample were anti-HCV-negative,
but HCV viremia may be present in the absence of
detectable HCV antibodies in HIV, although this occurs
only rarely [31,32]. The retrospective study design did not
permit us to test patients' sera for HCV RNA.
Fifth, we cannot exclude the possibility that some indi-
viduals were misclassified by APRI due to conditions
which can decrease the platelet count (e.g., HIV-associ-
ated idiopathic thrombocytopenic purpura) or which
transiently increase serum AST levels (e.g., ART-associ-
ated hepatotoxicity). Hepatic fibrosis would be ideally
assessed by liver biopsy, but the acceptability, cost, and
risk of liver biopsy among HIV-monoinfected patients
make such a study impractical. APRI has been validated
to identify significant hepatic fibrosis in HIV/HCV-coin-
fected patients [8] with a high degree of accuracy, but it
has not been validated against liver biopsy in HIV-
monoinfected patients. APRI compares favorably with
other non-invasive biomarkers such as the FIB-4, MUL-
TIVIRC equation, and Forns index that do not incorpo-
rate the same parameters [33].
Finally, our exclusion of subjects from certain CFAR
sites, particularly the Philadelphia Veterans Affairs Medi-
cal Center and adolescent HIV clinic at the Children's
Hospital of Philadelphia, due to the inability to obtain
computerized laboratory results, potentially limits the
generalizability of the study results.
Conclusion
Our study found that 8% of HIV-monoinfected patients
had significant liver fibrosis by APRI. Diabetes mellitus
and HIV viremia were both risk factors for significant
fibrosis by APRI. These results suggest the need for
future longitudinal studies to examine liver fibrosis in
HIV-monoinfected patients.
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